Table 1 Comparison between WHO, RECIST, and RECIST 1.1 Criteria
From: Imaging biomarkers for evaluating tumor response: RECIST and beyond
| Â | WHO | RECIST | RECIST 1.1 |
|---|---|---|---|
Lesion measurement | |||
 Imaging modalities | N/A | Chest X-ray, CT, and MRI | Chest X-ray, CT, MRI, and 18 F-FDG PET |
 Limitation of measurable lesions | N/A | • 10 mm on spiral CT • 20 mm on non-spiral CT or MRI • Chest X-ray: if clearly defined • Clinical: 20 mm | • 10 mm on CT/MRI (slice thickness ≤ 5 mm), or 2 x slice thickness (if thickness > 5 mm ) • Chest X-ray: 20 mm • Clinical: 10 mm (must be measurable with calipers) •18 F-FDG PET: included only in the detection of new lesions |
 Lymph node | Unspecified | Unspecified | CT: short axis • ≥ 15 mm is measurable, target lesion • 10–14 mm is non-measurable, non-target lesion • < 10 mm is normal |
 Method of measurement | Cross-product of the longest diameter and the longest perpendicular diameter | Longest diameter in the axial plane | Longest diameter in the axial plane |
 Numbers of lesions measured | N/A | up to 10 lesions (≤ 5 in any one organ) | up to 5 lesions (≤ 2 in any one organ) |
Response evaluation | |||
 Complete Response (CR) | Disappearance of all lesions | Disappearance of all lesions | Disappearance of all lesions and pathologic lymph nodes |
 Partial Response (PR) | ≥ 50 % decrease in the sum of the area | ≥ 30 % decrease in the sum of the longest diameter | ≥ 30 % decrease in the sum of the longest diameter |
 Stable Disease (SD) | Neither PR nor PD | Neither PR nor PD | Neither PR nor PD |
 Progressive Disease (PD) | ≥ 25 % increase in the sum of the area | ≥ 20 % increase in the sum of longest diameters, or new lesions | ≥ 20 % increase in the sum of longest diameters with an absolute increase of ≥ 5 mm, or new lesions |